文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌根治性放疗后局部复发的挽救性再放疗:HDRB或局灶SBRT

Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
PubMed 文献 · Radiat Oncol · 2017-03-09

本研究回顾性评估了28例前列腺癌根治性放疗后局部复发患者接受挽救性再放疗(HDRB 10例或局灶SBRT 18例,方案均为35 Gy/5次)的毒性和可行性。中位随访22.5个月,HDRB组90%出现生物学反应、50%维持bNED,SBRT组55.6%维持bNED;两组各出现1例3级或4级短暂泌尿毒性,无3-4级消化道毒性。结论认为再放疗可行且毒性低,但需进一步研究确认。

要点

  • 前列腺癌根治性放疗后局部复发,HDRB或局灶SBRT挽救再放疗方案为35 Gy/5次。
  • HDRB组90%生物学反应、50% bNED;SBRT组55.6% bNED。
  • 两组各1例3级或4级短暂泌尿毒性,无3-4级消化道毒性。

核心结论

  • 前列腺癌根治性放疗后局部复发采用HDRB或局灶SBRT挽救再放疗可行,毒性发生率低。
  • 需进一步研究确认这些发现并确定可能获益患者的预测特征。

研究设计与样本

  • 回顾性研究,纳入2011至2015年28例影像和/或活检证实的前列腺内复发患者。
  • 挽救再放疗采用HDRB(n=10,全前列腺)或局灶SBRT(n=18,CyberKnife®直线加速器)。
  • 再放疗方案为35 Gy分5次。

主要发现

  • 中位随访22.5个月(IQR=8-42),HDRB组9例(90%)出现阳性生物学反应,5例(50%)随访结束时维持bNED。
  • HDRB组初始有反应者中,中位19.5个月(IQR=11.5-26)后BCR率为44.4%。
  • SBRT组中位随访14.5个月(IQR=7-23),18例中10例(55.6%)维持bNED。
  • SBRT组初始有反应的15例中,5例(33.3%)出现BCR。
  • HDRB组1例出现短暂3级泌尿并发症;SBRT组1例出现短暂4级泌尿并发症。

关键数值与推荐

  • 再放疗剂量方案为35 Gy分5次。
  • 毒性按CTCAE v4.03评估并与基线比较;随访结束时所有评估患者泌尿状态分级变化≤+1级。
  • 未观察到3-4级消化道毒性。

临床怎么用

  • 对于根治性放疗后前列腺内局部复发,可考虑HDRB或局灶SBRT挽救再放疗。
  • 再放疗后需密切监测泌尿毒性及PSA生物学反应。

局限性

  • 回顾性研究,样本量小(28例)。
  • HDRB组与SBRT组随访时间不同,HDRB组中位22.5个月,SBRT组中位14.5个月。
  • 作者指出需进一步研究确认发现并确定获益患者的预测特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the feasibility of a prostate re-irradiation after definitive radiation therapy failure. Two modalities were investigated: high-dose-rate brachytherapy (HDRB) on whole prostate gland and focal stereotactic radiotherapy (SBRT) using CyberKnife® linac. METHODS: Between 2011 and 2015, 28 patients with imaged and/or biopsy-proven intra-prostatic recurrence of cancer after definitive radiation therapy underwent a salvage re-irradiation using HDRB (n = 10) or focal SBRT (n = 18). The schedule of re-irradiation was 35 Gy in 5 fractions. Biological response (defined as post-salvage radiation PSA variation) and biochemical no-evidence of disease (bNED) were evaluated in the whole cohort. For patients who had a positive biological response after salvage radiation, biochemical recurrence (BCR) and survival after salvage radiotherapy were evaluated. Post-salvage toxicities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and were compared to baseline status. RESULTS: Within a median follow-up of 22.5 months (IQR = 8-42), 9 (90%) patients experienced a positive biological response after salvage HDRB and 5 (50%) remained bNED at the end of the follow-up. Among patients who initially responded to salvage HDRB, the BCR rate was 44.4% after a median interval of 19.5 months (IQR = 11.5-26). Only one patient experienced a transient grade 3 urinary complication. In the SBRT group, the median follow-up was 14.5 months (IQR = 7-23) and 10 (55.6%) out of the 18 patients remained bNED. Among the 15 patients who initially responded to salvage SBRT, 5 (33.3%) experienced a BCR. One patient experienced a transient grade 4 urinary complication. At the end of the follow-up, all evaluated patients had a urinary status grade variation ≤ +1 grade. No grade 3-4 digestive toxicity was observed. CONCLUSIONS: Salvage prostate re-irradiation for locally recurrent cancer is feasible and generate low toxicities rates when using with HDRB or focal SBRT. However, further investigations are necessary to confirm these findings and to determine predictive features for patients who might benefit from such an approach.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mbeutcha A, Chauveinc L, Bondiau PY, et al. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol. 2017. PMID: 28274241. doi:10.1186/s13014-017-0789-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。